Upregulation of nuclear PA28γ expression in cirrhosis and hepatocellular carcinoma

Motoi Kondo, Kohji Moriishi, Hiroshi Wada, Takehiro Noda, Shigeru Marubashi, Kenichi Wakasa, Yoshiharu Matsuura, Yuichiro Doki, Masaki Mori, Hiroaki Nagano

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We previously reported that proteasome activator 28γ (PA28γ) is an oncogenic protein in hepatitisC virus (HCV) core protein transgenic mice. The aim of this study was to determine the role of PA28γ expression at the protein level in the development and progression of human hepatocarcinogenesis and hepatocellular carcinoma (HCC). Samples from tissues representing a wide spectrum of liver disease were analyzed, including histologically normal livers (n=5), HCV-related chronic hepatitis (CH) (n=15) and cirrhosis (n=31). The level of nuclear PA28γ increased with the progression of liver disease from CH to cirrhosis. The majority of cirrhotic livers (68%; 21/31) displayed high nuclear PA28γ expression. However, in half of the HCCs (50%; 18/36), little or no nuclear PA28γ expression was observed, while the remaining 50% (18/36) of the cases displayed high levels of nuclear PA28γ expression. A clinicopathological survey demonstrated a significant correlation between nuclear PA28γ expression and capsular invasion in HCC (P=0.026); a striking difference was found between nuclear PA28γ expression in non-tumor tissues and shorter disease-free survival (P<0.01). Moreover, nuclear PA28γ expression in non-tumor tissues correlated with the expression of molecules related to the genesis of hepatic steatosis and HCC, such as sterol regulatory element binding protein-1c mRNA. The findings suggest the involvement of nuclear PA28γ expression in the progression and relapse of HCC, and suggest that nuclear PA28γ is a potentially suitable target for the prevention and/or treatment of HCC.

Original languageEnglish
Pages (from-to)379-385
Number of pages7
JournalExperimental and Therapeutic Medicine
Volume3
Issue number3
DOIs
Publication statusPublished - Mar 1 2012
Externally publishedYes

Fingerprint

Proteasome Endopeptidase Complex
Hepatocellular Carcinoma
Fibrosis
Up-Regulation
Chronic Hepatitis
Liver Diseases
Liver
Sterol Regulatory Element Binding Protein 1
Viral Core Proteins
Human Development
Transgenic Mice
Disease-Free Survival
Proteins
Viruses
Recurrence
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Cancer Research
  • Immunology and Microbiology (miscellaneous)

Cite this

Kondo, M., Moriishi, K., Wada, H., Noda, T., Marubashi, S., Wakasa, K., ... Nagano, H. (2012). Upregulation of nuclear PA28γ expression in cirrhosis and hepatocellular carcinoma. Experimental and Therapeutic Medicine, 3(3), 379-385. https://doi.org/10.3892/etm.2011.415

Upregulation of nuclear PA28γ expression in cirrhosis and hepatocellular carcinoma. / Kondo, Motoi; Moriishi, Kohji; Wada, Hiroshi; Noda, Takehiro; Marubashi, Shigeru; Wakasa, Kenichi; Matsuura, Yoshiharu; Doki, Yuichiro; Mori, Masaki; Nagano, Hiroaki.

In: Experimental and Therapeutic Medicine, Vol. 3, No. 3, 01.03.2012, p. 379-385.

Research output: Contribution to journalArticle

Kondo, M, Moriishi, K, Wada, H, Noda, T, Marubashi, S, Wakasa, K, Matsuura, Y, Doki, Y, Mori, M & Nagano, H 2012, 'Upregulation of nuclear PA28γ expression in cirrhosis and hepatocellular carcinoma', Experimental and Therapeutic Medicine, vol. 3, no. 3, pp. 379-385. https://doi.org/10.3892/etm.2011.415
Kondo, Motoi ; Moriishi, Kohji ; Wada, Hiroshi ; Noda, Takehiro ; Marubashi, Shigeru ; Wakasa, Kenichi ; Matsuura, Yoshiharu ; Doki, Yuichiro ; Mori, Masaki ; Nagano, Hiroaki. / Upregulation of nuclear PA28γ expression in cirrhosis and hepatocellular carcinoma. In: Experimental and Therapeutic Medicine. 2012 ; Vol. 3, No. 3. pp. 379-385.
@article{6d3087c3bfc04ee086f0c0fc7b4d1678,
title = "Upregulation of nuclear PA28γ expression in cirrhosis and hepatocellular carcinoma",
abstract = "We previously reported that proteasome activator 28γ (PA28γ) is an oncogenic protein in hepatitisC virus (HCV) core protein transgenic mice. The aim of this study was to determine the role of PA28γ expression at the protein level in the development and progression of human hepatocarcinogenesis and hepatocellular carcinoma (HCC). Samples from tissues representing a wide spectrum of liver disease were analyzed, including histologically normal livers (n=5), HCV-related chronic hepatitis (CH) (n=15) and cirrhosis (n=31). The level of nuclear PA28γ increased with the progression of liver disease from CH to cirrhosis. The majority of cirrhotic livers (68{\%}; 21/31) displayed high nuclear PA28γ expression. However, in half of the HCCs (50{\%}; 18/36), little or no nuclear PA28γ expression was observed, while the remaining 50{\%} (18/36) of the cases displayed high levels of nuclear PA28γ expression. A clinicopathological survey demonstrated a significant correlation between nuclear PA28γ expression and capsular invasion in HCC (P=0.026); a striking difference was found between nuclear PA28γ expression in non-tumor tissues and shorter disease-free survival (P<0.01). Moreover, nuclear PA28γ expression in non-tumor tissues correlated with the expression of molecules related to the genesis of hepatic steatosis and HCC, such as sterol regulatory element binding protein-1c mRNA. The findings suggest the involvement of nuclear PA28γ expression in the progression and relapse of HCC, and suggest that nuclear PA28γ is a potentially suitable target for the prevention and/or treatment of HCC.",
author = "Motoi Kondo and Kohji Moriishi and Hiroshi Wada and Takehiro Noda and Shigeru Marubashi and Kenichi Wakasa and Yoshiharu Matsuura and Yuichiro Doki and Masaki Mori and Hiroaki Nagano",
year = "2012",
month = "3",
day = "1",
doi = "10.3892/etm.2011.415",
language = "English",
volume = "3",
pages = "379--385",
journal = "Experimental and Therapeutic Medicine",
issn = "1792-0981",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Upregulation of nuclear PA28γ expression in cirrhosis and hepatocellular carcinoma

AU - Kondo, Motoi

AU - Moriishi, Kohji

AU - Wada, Hiroshi

AU - Noda, Takehiro

AU - Marubashi, Shigeru

AU - Wakasa, Kenichi

AU - Matsuura, Yoshiharu

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Nagano, Hiroaki

PY - 2012/3/1

Y1 - 2012/3/1

N2 - We previously reported that proteasome activator 28γ (PA28γ) is an oncogenic protein in hepatitisC virus (HCV) core protein transgenic mice. The aim of this study was to determine the role of PA28γ expression at the protein level in the development and progression of human hepatocarcinogenesis and hepatocellular carcinoma (HCC). Samples from tissues representing a wide spectrum of liver disease were analyzed, including histologically normal livers (n=5), HCV-related chronic hepatitis (CH) (n=15) and cirrhosis (n=31). The level of nuclear PA28γ increased with the progression of liver disease from CH to cirrhosis. The majority of cirrhotic livers (68%; 21/31) displayed high nuclear PA28γ expression. However, in half of the HCCs (50%; 18/36), little or no nuclear PA28γ expression was observed, while the remaining 50% (18/36) of the cases displayed high levels of nuclear PA28γ expression. A clinicopathological survey demonstrated a significant correlation between nuclear PA28γ expression and capsular invasion in HCC (P=0.026); a striking difference was found between nuclear PA28γ expression in non-tumor tissues and shorter disease-free survival (P<0.01). Moreover, nuclear PA28γ expression in non-tumor tissues correlated with the expression of molecules related to the genesis of hepatic steatosis and HCC, such as sterol regulatory element binding protein-1c mRNA. The findings suggest the involvement of nuclear PA28γ expression in the progression and relapse of HCC, and suggest that nuclear PA28γ is a potentially suitable target for the prevention and/or treatment of HCC.

AB - We previously reported that proteasome activator 28γ (PA28γ) is an oncogenic protein in hepatitisC virus (HCV) core protein transgenic mice. The aim of this study was to determine the role of PA28γ expression at the protein level in the development and progression of human hepatocarcinogenesis and hepatocellular carcinoma (HCC). Samples from tissues representing a wide spectrum of liver disease were analyzed, including histologically normal livers (n=5), HCV-related chronic hepatitis (CH) (n=15) and cirrhosis (n=31). The level of nuclear PA28γ increased with the progression of liver disease from CH to cirrhosis. The majority of cirrhotic livers (68%; 21/31) displayed high nuclear PA28γ expression. However, in half of the HCCs (50%; 18/36), little or no nuclear PA28γ expression was observed, while the remaining 50% (18/36) of the cases displayed high levels of nuclear PA28γ expression. A clinicopathological survey demonstrated a significant correlation between nuclear PA28γ expression and capsular invasion in HCC (P=0.026); a striking difference was found between nuclear PA28γ expression in non-tumor tissues and shorter disease-free survival (P<0.01). Moreover, nuclear PA28γ expression in non-tumor tissues correlated with the expression of molecules related to the genesis of hepatic steatosis and HCC, such as sterol regulatory element binding protein-1c mRNA. The findings suggest the involvement of nuclear PA28γ expression in the progression and relapse of HCC, and suggest that nuclear PA28γ is a potentially suitable target for the prevention and/or treatment of HCC.

UR - http://www.scopus.com/inward/record.url?scp=84855846618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855846618&partnerID=8YFLogxK

U2 - 10.3892/etm.2011.415

DO - 10.3892/etm.2011.415

M3 - Article

AN - SCOPUS:84855846618

VL - 3

SP - 379

EP - 385

JO - Experimental and Therapeutic Medicine

JF - Experimental and Therapeutic Medicine

SN - 1792-0981

IS - 3

ER -